Aug 2026· International Journal of Innovative Technologies in Social Science· Vol 2· 0 citations· 22 references
TL;DR
Antidepressants appear to have a role in IBS management, with the most consistent evidence observed for TCAs, and Interpretation is constrained by variability in outcome measures and study design.
Abstract
Background: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which antidepressants are used to modulate pathways involved in symptom generation. Evidence for their efficacy remains heterogeneous across drug classes and outcomes.
Aim: To systematically evaluate the efficacy of antidepressants in the treatment of IBS across pharmacological classes and outcome domains.
Methods: The methodology and reporting structure of this review were informed by the PRISMA framework. Literature searches were conducted in PubMed and Google Scholar to identify studies evaluating antidepressants in adults with irritable bowel syndrome diagnosed according to Rome criteria. Randomized controlled trials were considered the primary source of evidence and were supplemented, where relevant, by open-label, mechanistic, and exploratory studies. Eligible studies reported validated clinical outcomes, including IBS symptom severity, abdominal pain, global improvement, and health-related quality of life. Owing to differences in study design, interventions, and outcome measures, findings were synthesized qualitatively.
Results: Tricyclic antidepressants (TCAs) demonstrated the most consistent signal of benefit, particularly for IBS symptom severity, global improvement, and abdominal pain. Selective serotonin reuptake inhibitors (SSRIs) showed inconsistent findings across trials, with effects varying by outcome measure and study design. Evidence for serotonin–norepinephrine reuptake inhibitors (SNRIs) was limited, often derived from add-on or open-label studies, although some randomized trials reported improvements in symptom severity and quality of life. Data for other antidepressants were restricted to a small number of RCTs with endpoint-specific effects. Variability in outcome measures, including IBS-SSS, adequate relief, and quality-of-life instruments, contributed to heterogeneity in reported treatment effects.
Conclusions: Antidepressants appear to have a role in IBS management, with the most consistent evidence observed for TCAs. Findings for SSRIs are inconclusive, while evidence for SNRIs and other agents remains limited. Interpretation is constrained by variability in outcome measures and study design. Further well-designed RCTs using standardized endpoints are required to better define the role of antidepressants in IBS.
BACKGROUND
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by recurrent abdominal pain and altered bowel habits, with substantial effects on quality of life and healthcare utilization. Melatonin has been proposed as a potential adjunctive therapy because of its effects on visc...
Ghadeer Mahdi, Noor Abotaiban, A. Gadelmawla et al.· Journal of Gastroenterology...· 0 citations
BACKGROUND AND AIMS
Persistent IBS-like symptoms affect up to one-third of patients with inflammatory bowel disease (IBD) in remission, representing a major unmet need not addressed by anti-inflammatory therapies. Despite increasing use of dietary and gut-brain-targeted strategies, their efficacy in this population rem...
M. Goyal, Allen A. Lee, Dhruvi Shah et al.· Clinical Gastroenterology an...· 0 citations
Berberine combined with brain-gut axis-targeted medications shows promising efficacy and acceptable safety in the treatment of IBS-D, however, existing studies are limited by small sample sizes and methodological weaknesses, and the overall strength of evidence remains insufficient.
Nan-Xi Liu, Ya-Hui Huang, Hui-Xia Qiao et al.· Frontiers in Pharmacology· 0 citations
Background: Generalized anxiety disorder (GAD) is a persistent mental illness that causes significant distress and impairment in functioning. Selective serotonin reuptake inhibitors (SSRIs) are often used in the treatment of GAD, but evidence for fluoxetine in particular is not as well established as for some other pha...
Sehasbir Singh, Haseeb Mohammad· Journal of Pharmaceutical Te...· 0 citations
This narrative review summarizes current evidence on the pathogenesis, diagnosis, and long term management of pediatric IBS, with emphasis on gut brain interactions, psychosocial factors, recent pediatric guidelines, and pharmacological and non-pharmacological interventions.
Agata Leszek, Michał Stermach, Z. Lecyk et al.· Archiv Euromedica· 0 citations
Probiotic supplementation may provide a modest adjunctive benefit for depressive symptoms in adults with MDD, however, the limited number of independent cohorts, clinical heterogeneity, risk-of-bias concerns, and imprecision resulted in low-certainty evidence according to GRADE.
M. Y. Alsmadi· Natural Resources for Human...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.